LianBio Announces Presentation Of Data From Phase 2a Study Of Infigratinib In Patients With Gastric Cancer At ESMO Congress 2023
LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the presentation of efficacy and safety data from a Phase